Our deep understanding of the coagulation cascade is leading our exploration of Factor XIa inhibition in collaboration with Johnson & Johnson Innovative Medicine. Together, our goal is to improve the risk-benefit profile of stroke prevention treatment for patients living with thrombotic conditions. Learn more about our FXIa research: https://bit.ly/4gRRHCd #WTDay24 #OneBMS
Bristol Myers Squibb
Pharmaceutical Manufacturing
Lawrence Township, NJ 1,482,395 followers
About us
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
- Website
-
http://www.bms.com
External link for Bristol Myers Squibb
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Lawrence Township, NJ
- Type
- Public Company
- Specialties
- biotechnology, innovation, great place to work, pharmaceuticals, research and development, and healthcare
Locations
Employees at Bristol Myers Squibb
-
Bill Trebasky
Biopharmaceuticals Operations Executive
-
Mark Kaplan
Senior Director Translational Oncology
-
Lisa Filaferro, MBA, PHR
-
Lakshman Nagesh Yerramalla
PMO Executive Leader & Transformations Specialist ⇨ PMO Strategy & Optimization | Business Transformation Leadership | Strategic Portfolio Management…
Updates
-
We are dedicated to making a meaningful impact on #EosinophilicEsophagitis (EoE) treatment by working to advance patient care. We recently completed a global Phase 3 clinical trial with the goals of both bringing a safe and effective treatment to patients and increasing overall understanding of the disease. Learn more about EoE: https://bit.ly/4gLQZGy #UEGWeek
-
#NationalComingOutDay is a time to honor the courage of those who have come out and to recognize the journey for those who are not yet able to. Our value of inclusion informs who we are and how we do business, and we are leading by example to address critical health disparities in communities that are often ignored, including the LGBTQI+ community. Learn more about our efforts here: https://bit.ly/4eSarje #OneBMS
-
As some of the industry’s most decorated recipients of the American Chemical Society Heroes of Chemistry award, our chemists accepted their seventh recognition in the last decade. This year, we celebrate their collaborative work with Amgen to deliver a first-in-class oral treatment approved for people living with plaque psoriasis. Learn more about how our teams are approaching science to transform global discovery, development and delivery of treatments for patients living with serious diseases: https://bit.ly/3U3Q6PP #OneBMS
-
Join our Chairman and CEO Chris Boerner at the STAT Summit virtually or live in Boston on Oct. 16 for a conversation with Matthew Herper about his vision for the future and how we’re transforming the lives of patients through science. Register to watch or attend #STATSummit here: https://bit.ly/3zK8BC5 #OneBMS
-
We're honored to be on Forbes' World's Best Employers list in recognition of our talent development and best-in-class benefits. Our global workforce is vital to our mission to transform the lives of patients through science and to advance our culture of inclusion. Learn more: https://bit.ly/4dJNk9s #OneBMS
-
There are two sides of the coin when it comes to treating #Alzheimers disease – disease modification and symptom management. Scientists in our neuroscience thematic research center are working toward tackling this duality of needs. With two distinct scientific approaches, they are pursuing investigational therapeutics that aim to slow disease progression and help patients and their families better manage the myriad of associated symptoms which severely impact day to day life. Explore our efforts to provide a continuum of care for patients living with Alzheimer’s disease: https://bit.ly/4gY18jo #OneBMS
-
Our Universal Patient Language (UPL) team ensures our patients and caregivers can better understand the materials that we give them to appropriately educate themselves and work towards better healthcare decisions and outcomes. Learn more about how the UPL team is helping to get more medicines to patients faster. https://bit.ly/4eyIooR #OneBMS
-
We're thrilled to share that Alyssa Johnsen, M.D., Ph.D., senior vice president and head of clinical development for Immunology, Cardiovascular and Neuroscience, has been recognized in the #PharmaVoice100, spotlighting the top 100 leaders in the pharmaceutical industry. Alyssa has been recognized for her outstanding contributions to clinical development, driving meaningful change and setting new standards in our industry. https://bit.ly/3NiMvcT #OneBMS
-
Dr. Rishi Kakar, investigator in the EMERGENT program, shares his thoughts on the recent FDA approval of a new class of medicine for the treatment of #schizophrenia in adults. We wish to extend our deepest appreciation to the patients, researchers and healthcare professionals who participated in the trials, without whom this landmark approval would not have been possible. Learn more: https://bit.ly/3YeakbT
Affiliated pages
Similar pages
Browse jobs
Stock
BMY
NYSE
20 minutes delay
$52.20
-0.2 (-0.382%)
- Open
- 52.58
- Low
- 52
- High
- 52.66
Data from Refinitiv
See more info on